Compare TRNS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNS | ESPR |
|---|---|---|
| Founded | 1964 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.5M | 816.9M |
| IPO Year | 1995 | 2013 |
| Metric | TRNS | ESPR |
|---|---|---|
| Price | $88.86 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $116.00 | $8.75 |
| AVG Volume (30 Days) | 178.4K | ★ 8.9M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ 0.57 | N/A |
| Revenue | $331,877,000.00 | ★ $403,135,000.00 |
| Revenue This Year | $21.75 | N/A |
| Revenue Next Year | $7.55 | $12.81 |
| P/E Ratio | $156.19 | ★ N/A |
| Revenue Growth | 19.20 | ★ 21.31 |
| 52 Week Low | $50.23 | $1.10 |
| 52 Week High | $94.76 | $4.18 |
| Indicator | TRNS | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 64.86 |
| Support Level | $86.10 | $3.13 |
| Resistance Level | $94.48 | $3.18 |
| Average True Range (ATR) | 3.75 | 0.02 |
| MACD | -0.58 | -0.01 |
| Stochastic Oscillator | 28.98 | 75.00 |
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.